Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Children With Solid Tumors
Sponsor: Baylor College of Medicine
Listed as NCT04377932, this PHASE1 trial focuses on Liposarcoma and Liver Cancer and remains ongoing. Sponsored by Baylor College of Medicine, it has been updated 17 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
17 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE1
▶ Show 12 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .